Cost-Effectiveness of Interventions for Anxiety and Depressive Disorders

Mihalopoulos, Cathrine; Chatterton, Mary Lou

doi:10.1007/978-3-319-55266-8_18

Cited by 5 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These unknowns highlight the current lack of clarity around what the provision of psychedelic-assisted psychotherapy will look like in Australia and who will be able to access it. 30 Prospective research is needed now that psychedelics can be prescribed to truly understand their impact on treating mental health conditions in Australia, including their associated economic and societal costs and/or benefits. In the short-term, high-quality review-level evidence is required to address misinformation and reduce fears related to the perceived negative effects of psychedelics.…”

Section: Future Researchmentioning

confidence: 99%

“We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions

Kunstler,

Smith,

Langmead

et al. 2023

Public Health Res Pract.

View full text Add to dashboard Cite

show abstract

Section: Future Researchmentioning

confidence: 99%

“We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions

Kunstler,

Smith,

Langmead

et al. 2023

Public Health Res Pract.

View full text Add to dashboard Cite

show abstract

“…By deepening this knowledge, it may be possible to further optimize anxiety treatments to promote a faster and more sustainable improvement of anxiety symptoms. This in turn could relieve health care systems and economies around the world from the distinct burden of high anxiety rates [ 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Neural Processing of Cognitive Control in an Emotionally Neutral Context in Anxiety Patients

et al. 2021

View full text Add to dashboard Cite

Impaired cognitive control plays a crucial role in anxiety disorders and is associated with deficient neural mechanisms in the fronto-parietal network. Usually, these deficits were found in tasks with an emotional context. The present study aimed at investigating electrophysiological and vascular signatures from event-related brain potentials (ERPs) and functional near-infrared spectroscopy (fNIRS) in anxiety patients versus healthy controls during an inhibition task integrated in an emotionally neutral context. Neural markers were acquired during the completion of a classical Eriksen flanker task. The focus of data analysis has been the ERPs N200 and P300 and fNIRS activations in addition to task performance. No behavioral or neural group differences were identified. ERP findings showed a larger N2pc and a delayed and reduced P300 for incongruent stimuli. The N2pc modulation suggests the reorienting of attention to salient stimuli, while the P300 indicates longer lasting stimulus evaluation processes due to increased task difficulty. FNIRS did not result in any significant activation potentially suggesting a contribution from deeper brain areas not measurable with fNIRS. The missing group difference in our non-emotional task indicates that no generalized cognitive control deficit but rather a more emotionally driven deficit is present in anxiety patients.

show abstract

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

et al. 2020

View full text Add to dashboard Cite

Cost-Effectiveness of Interventions for Anxiety and Depressive Disorders

Cited by 5 publications

References 49 publications

“We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions

“We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions

Neural Processing of Cognitive Control in an Emotionally Neutral Context in Anxiety Patients

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

Contact Info

Product

Resources

About